Shilpa Medicare Limited has fixed Friday, September 4, 2026, as the record date for determining shareholders entitled to the final dividend for the financial year 2025-26. This action follows the Board of Directors' recommendation of the dividend at its meeting on August 5, 2026, subject to approval by members at the upcoming Annual General Meeting (AGM). The declaration is contingent upon shareholder ratification at the 39th AGM scheduled for September 11, 2026.

Dividend and Corporate Actions

The company notified the stock exchanges on August 5, 2026, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholders holding shares on the record date will be eligible to receive the dividend if it is approved at the AGM. Payment or dispatch of the dividend will occur within the statutory time limit from the date of approval.

Remote e-voting for the AGM will commence on Monday, September 7, 2026, at 09:00 AM and conclude on Thursday, September 10, 2026, at 05:00 PM. M/s KFin Technologies Limited has been engaged to facilitate the e-voting process. The AGM itself will be held via video conferencing at 11:00 AM on September 11, 2026.

Q1FY26 Financial Results

Alongside the dividend announcement, Shilpa Medicare reported strong financial performance for the quarter ended June 30, 2026. Consolidated net profit attributable to owners more than doubled year-on-year to ₹10,088 lakhs from ₹4,688 lakhs in Q1FY25. Consolidated revenue from operations rose to ₹46,578 lakhs, up from ₹32,147 lakhs in the corresponding quarter of the previous year.

On a standalone basis, net profit increased significantly to ₹6,492 lakhs from ₹1,871 lakhs. This growth was partly driven by a one-time deferred tax liability reversal of ₹2,684 lakhs following a reassessment under the new tax regime. Standalone revenue from operations nearly doubled to ₹18,904 lakhs from ₹9,346 lakhs.

Strategic Investments and Appointments

The Board approved an investment of up to EUR 7 million by its wholly owned subsidiary, Shilpa Biocare Private Limited, in Gate2Brain (G2B). The investment will be executed through a combination of cash infusion, equity for services, and project development, marking a strategic long-term equity partnership.

Additionally, the Board approved the reappointment of Mr. Sharath Reddy Kalakota as Whole Time Director, subject to member approval at the AGM. Mr. Kalakota brings over three decades of experience in API manufacturing. The Board also sanctioned the Scheme of Merger by Absorption of Shilpa Therapeutics Private Limited, with financials restated accordingly.

Shilpa Medicare reported a robust set of financial results for Q1, with consolidated net profit more than doubling on a year-on-year basis. Revenue and operating profitability both recorded significant improvements, underscoring the company's growth momentum during the quarter.

Strong Revenue and Profit Growth

Shilpa Medicare's consolidated net profit climbed to 1B rupees in Q1, compared to 470M rupees in the corresponding quarter of the previous year — representing a substantial year-on-year increase. Revenue for the quarter came in at 4.7B rupees, up from 3.2B rupees in the same period last year, reflecting meaningful top-line expansion.

The following table summarises the key financial metrics for the quarter:

Operating Profitability Improves

On the operating front, EBITDA rose to 1.36B rupees from 916M rupees in the year-ago quarter, reflecting improved operational efficiency and scale. The EBITDA margin expanded to 29.3% from 28.51% on a year-on-year basis, indicating that revenue growth was accompanied by disciplined cost management. The combination of higher revenues and improved margins contributed to the significant jump in net profitability during the quarter.